Skip to main content
SpringerLink
Log in
Book cover

Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents pp 75–97Cite as

Monitoring and Measuring Drug Effects. I. Physical Effects

  • Chapter

Abstract

The decision to use psychoactive medications in children and adolescents is not taken lightly by parents or clinicians. Medications are often utilized after periods of behavioral therapy or psychotherapeutic approaches have failed to ameliorate adequately the presenting symptoms.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abramowicz M: Sudden death in children treated with a tricyclic antidepressant. Med Lett Drugs Ther 32: 53, 1990.

    Google Scholar 

  2. Riddle MA, Nelson JC, Kleinman CS, et al: Sudden death in children receiving Norpramin: A review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 30: 104–108, 1991.

    Article  PubMed  CAS  Google Scholar 

  3. Gittelman-Klein R, Spitzer RL, Cantwell D: Diagnostic classifications and psychopharmacological indications, in Werry JS (ed): Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, Brunner/Mazel, 1978, pp 136–167.

    Google Scholar 

  4. Campbell M, Palij, M: Measurement of side effects including tardive dyskinesia, Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21(4): 1063–1066, 1985.

    CAS  Google Scholar 

  5. Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21 (4), 1985.

    Google Scholar 

  6. Guy W: Dosage Record and Treatment Emergent Symptoms Scale, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 223–244.

    Google Scholar 

  7. Guy W: Treatment Emergent Symptoms Scale—Write-In, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 341–345.

    Google Scholar 

  8. Guy W: Subjects Treatment Emergent Symptoms Scale, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 347–350.

    Google Scholar 

  9. Guy W: Abnormal Involuntary Movement Scale, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 534–537.

    Google Scholar 

  10. Campbell M, Green WH, Deutsch SI: Child and Adolescent Psychopharmacology. Beverly Hills, Sage Publications, 1985, pp 11–42.

    Google Scholar 

  11. Guy W: Physical and Neurological Examination for Soft Signs, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 383–406.

    Google Scholar 

  12. Denckla MB: Revised neurological examination for subtle signs, Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21(4): 773–789, 1985.

    CAS  Google Scholar 

  13. Sleator EK: Measurement of compliance, Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21(4): 1089–1093, 1985.

    CAS  Google Scholar 

  14. Khan AU: Biochemical profile of depressed adolescents. J Am Acad Child Adolesc Psychiatry 6: 873–878, 1987.

    Article  Google Scholar 

  15. Doherty M, Madansky D, Kraft J, et al: Cortisol dynamics and test performance of the dexamethasone suppression test in 97 psychiatrically hospitalized children aged 3-16 years. J Am Acad Child Psychiatry 25(3): 400–408, 1986.

    Article  Google Scholar 

  16. Klee S, Garfinkel B: Identification of depression in children and adolescents: The role of the dexamethasone suppression test. J Am Acad Child Psychiatry 23: 410–415, 1984.

    Article  PubMed  CAS  Google Scholar 

  17. Kinsbourne M: Disorders of mental development, in Menkes JH (ed): Textbook of Child Neurology, ed 3. Philadelphia, Lea & Febiger, 1985, pp 764–801.

    Google Scholar 

  18. Raj A, Sheehan D: Medical evaluation of panic attacks. J Clin Psychiatry 48: 309–313, 1987.

    PubMed  CAS  Google Scholar 

  19. Zametkin A, Rapoport J: Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years? J. Am Acad Child Adolesc Psychiatry 26: 676–686, 1987.

    Article  PubMed  CAS  Google Scholar 

  20. Bowden CL, Deutsch CK, Swanson JM: Plasma dopamine beta hydroxylase and platelet monoamine oxidase in attention deficit disorder and conduct disorder. J Am Acad Child Adolesc Psychiatry 27: 171–174, 1988.

    Article  PubMed  CAS  Google Scholar 

  21. Kruesi MJP: Cruelty to animals and CSF 5-HIAA. Psychiatry Res 28: 115–116, 1989.

    Article  PubMed  CAS  Google Scholar 

  22. Kruesi MJP, Linnoila M, Rapoport JL, et al: Carbohydrate craving, conduct disorder and low CSF 5-HIAA. Psychiatry Res 16: 83–86, 1985.

    Article  PubMed  CAS  Google Scholar 

  23. Kruesi MJP, Rapoport JL, Hamburger S, et al: CSF monoamine metabolites, aggression and impulsivity in disruptive behavior disorders of children and adolescents. Arch Gen Psychiatry 47: 419–426, 1990.

    Article  PubMed  CAS  Google Scholar 

  24. Diederich N, Ackerman R, Jurgens R, et al: Early involvement of the nervous system by human immune deficiency virus (HIV): A study of 79 patients. Eur Neurol 28: 93–103, 1988.

    Article  PubMed  CAS  Google Scholar 

  25. Leckman JF, Weissman MM, Pauls DL: Family-genetic studies and identification of valid diagnostic categories in adult and child psychiatry, Br J Psychiatry 151: 39–44, 1987.

    Article  PubMed  CAS  Google Scholar 

  26. Walzer S, et al: A method for the longitudinal study of behavioral development in infants and children: The early development of XXY children. J Child Psychol Psychiatry 19: 213–229, 1978.

    Article  PubMed  CAS  Google Scholar 

  27. Ratcliffe SG, Field MAS: Emotional disorder of XYY children: Four case reports. J Child Psychol Psychiatry 23: 401–406, 1982.

    Article  PubMed  CAS  Google Scholar 

  28. Nielsen J, Pelsen B, Sorenson K: Follow-up of 30 Klinefelter males treated with testosterone. Clin Genet 33: 262–269, 1988.

    Article  PubMed  CAS  Google Scholar 

  29. Dening T, Berrios G: Wilson’s disease: Psychiatric symptoms in 195 cases. Arch Gen Psychiatry 46: 1126–1134, 1989.

    Article  PubMed  CAS  Google Scholar 

  30. Courchesne E, Yeung-Courchesne R, Press G, et al: Hypoplasia of cerebellar vermal lobules VI and VII in autism. N Engl J Med 318: 1349–1354, 1988.

    Article  PubMed  CAS  Google Scholar 

  31. Chugani H: Personal communication.

    Google Scholar 

  32. Gwirtsman HE, Kaye WH, George DT, et al: Hyperamylasemia and its relationship to binge-purge episodes: Development of a clinically relevant laboratory test. J Clin Psychiatry 50(6): 196–204, 1989.

    PubMed  CAS  Google Scholar 

  33. Schoonover SC: Introduction: The practice of pharmacotherapy, in Bassuk EL, Schoonover SC, Gelenberg AJ (ed): The Practitioner’s Guide to Psychoactive Drugs, ed 2. New York, Plenum Press, 1983, pp 10–11.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section on Clinical Brain Imaging, Laboratory of Cerebral Metabolism, National Institute of Mental Health, Bethesda, Maryland, 20892, USA

    Alan J. Zametkin M.D. & Emily M. Yamada B.A.

Authors
  1. Alan J. Zametkin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emily M. Yamada B.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Auckland, Auckland, New Zealand

    John S. Werry M.D. (Emeritus Professor of Psychiatry) (Emeritus Professor of Psychiatry)

  2. The Nisonger Center for Mental Retardation and Developmental Disabilities, The Ohio State University, Columbus, Ohio, USA

    Michael G. Aman Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Zametkin, A.J., Yamada, E.M. (1993). Monitoring and Measuring Drug Effects. I. Physical Effects. In: Werry, J.S., Aman, M.G. (eds) Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2884-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2884-5_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-44389-3

  • Online ISBN: 978-1-4615-2884-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation